Vivatides Therapeutics, a biotechnology company focused on extrahepatic RNA-targeting therapeutics, has announced the successful closing of an oversubscribed $54 million Series A financing round.
The round was co-led by Qiming Venture Partners and a leading industry fund, with participation from Highlight Capital, TF Capital, and existing investor Apricot Capital. The funding will be used to advance the company’s extrahepatic delivery platform, accelerate multiple pipeline programs into clinical development, and expand its global team and research and development network.
Founded in 2025, Vivatides has rapidly progressed, completing both its seed and Series A financings within less than a year. The company is focused on overcoming one of the key limitations of RNA therapeutics, which historically have been largely restricted to liver-targeted applications due to delivery challenges.
RNA therapeutics are widely viewed as a major therapeutic modality, alongside small molecules and antibodies, due to their high specificity and ability to target a broad range of diseases. However, extrahepatic tissues remain underserved, representing a significant opportunity for innovation.
Vivatides is developing proprietary delivery technologies designed to enable RNA therapeutics to reach tissues beyond the liver. Its platform supports both siRNA and antisense oligonucleotides and incorporates advances in ligand conjugation, delivery efficiency, tissue targeting specificity, and safety. The company has reported encouraging in vivo results and is building a diversified pipeline supported by strong capabilities in sequence design and target discovery.
The leadership team includes experienced experts from leading RNA therapeutics companies who have contributed to multiple extrahepatic RNA programs, some of which have already progressed into clinical development.
Following the financing, Vivatides plans to accelerate preclinical optimization, advance IND-enabling studies, expand its R&D and management teams, and further strengthen its delivery platform. The company aims to address unmet medical needs in high-prevalence extrahepatic diseases and position itself as a leader in next-generation RNA therapeutics.
KEY QUOTES:
“Extrahepatic delivery is the key that will unlock RNA therapeutics from niche rare diseases to broad chronic indications. We are honored to have the support and recognition of leading investors. This financing will accelerate the evolution of our platform and pipeline, advancing innovative RNA therapeutics into extrahepatic disease areas. We believe that overcoming delivery barriers will enable RNA therapeutics to transform treatment paradigms across a wide range of diseases. We also look forward to engaging with more long-term, value-driven partners to bring transformative therapies to patients worldwide.”
Keming Zhou, Founder of Vivatides Therapeutics
“We have long been optimistic about the application potential of small nucleic acid drugs across a broader range of disease areas. Continuous advances in extrahepatic targeting technologies are steadily expanding their clinical frontiers. Vivatides Therapeutics has demonstrated solid technological expertise and efficient execution capabilities in this field, with encouraging progress achieved on its platform. We look forward to the company driving further technological breakthroughs, accelerating the clinical translation of its pipeline, and delivering safer and more effective innovative therapies to patients worldwide.”
Dr. Kan Chen, Partner at Qiming Venture Partners
“As an early investor in Vivatides’ seed round, we are delighted to see the company successfully complete its Series A financing and welcome new investors. Since its founding, Dr. Zhou and his team have consistently exceeded expectations with exceptional execution in platform development and pipeline advancement. We look forward to Vivatides translating its differentiated platform into breakthrough therapies that benefit patients worldwide and leading the next wave of extrahepatic RNA therapeutics.”
Dr. Wei Ding, Partner at Apricot Capital
